Methods for regulating endogenous production of dnase1
OwnerBradley G. Thompsoninventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the composition of one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for upregulating production of DNAse1 or a sub-peptide of DNAse1. Embodiments of the present disclosure can be used as a therapy or a treatment of a conditions including acute single organ injury including drug induced liver failure, aging, atelectasis, autism, cardiovascular disease, inflammatory autoimmune conditions including sarcoidosis, rheumatoid arthritis, lupus erythematosus, and granulomatosis, patients in ICU with any pathology, and systemic inflammatory response syndrome including conditions such as sepsis and those resulting from acute tissue injury such as trauma and acute myocardial infarction.
Claims24
A recombinant virus vector (RVV) comprising a virus with a gene insert that induces a target cell to increase production of human DNAse1 protein.
A method of making an agent/target cell complex, the method comprising a step of administering a recombinant virus vector (RVV) to a target cell for forming the agent/target cell complex, wherein the agent/target cell complex causes the target cell to increase a production of human DNAse1 protein.
A pharmaceutical agent comprising:
- a. an agent that upregulates production of a human DNAse1 protein;
- b. a pharmaceutically acceptable carrier;
- and/or
- c. an excipient.
A method of treating a condition, the method comprising a step of administering to a subject a therapeutically effective amount of an agent for upregulating the subject's production of human DNAse1 protein.
Dependencies are inferred from the claim text.